JP2010535506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535506A5 JP2010535506A5 JP2010519988A JP2010519988A JP2010535506A5 JP 2010535506 A5 JP2010535506 A5 JP 2010535506A5 JP 2010519988 A JP2010519988 A JP 2010519988A JP 2010519988 A JP2010519988 A JP 2010519988A JP 2010535506 A5 JP2010535506 A5 JP 2010535506A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- affinity reagent
- cancer
- matriptase
- matriptase stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003153 chemical reaction reagent Substances 0.000 claims 14
- 108010091175 Matriptase Proteins 0.000 claims 12
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 239000003183 carcinogenic agent Substances 0.000 claims 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 206010046766 uterine cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims 1
- 229940124651 anti-breast cancer agent Drugs 0.000 claims 1
- 229940124658 anti-colorectal cancer agent Drugs 0.000 claims 1
- 229930193936 anticarin Natural products 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000012642 immune effector Substances 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96383707P | 2007-08-07 | 2007-08-07 | |
| US60/963,837 | 2007-08-07 | ||
| PCT/US2008/009512 WO2009020645A2 (en) | 2007-08-07 | 2008-08-07 | Matriptase protein and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014155821A Division JP2014223083A (ja) | 2007-08-07 | 2014-07-31 | マトリプターゼタンパク質及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010535506A JP2010535506A (ja) | 2010-11-25 |
| JP2010535506A5 true JP2010535506A5 (enExample) | 2011-09-22 |
| JP5864856B2 JP5864856B2 (ja) | 2016-02-17 |
Family
ID=40239716
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519988A Expired - Fee Related JP5864856B2 (ja) | 2007-08-07 | 2008-08-07 | マトリプターゼタンパク質及びその使用 |
| JP2014155821A Withdrawn JP2014223083A (ja) | 2007-08-07 | 2014-07-31 | マトリプターゼタンパク質及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014155821A Withdrawn JP2014223083A (ja) | 2007-08-07 | 2014-07-31 | マトリプターゼタンパク質及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8420091B2 (enExample) |
| EP (1) | EP2185933B1 (enExample) |
| JP (2) | JP5864856B2 (enExample) |
| AU (1) | AU2008284271B2 (enExample) |
| DK (1) | DK2185933T3 (enExample) |
| ES (1) | ES2550754T3 (enExample) |
| WO (1) | WO2009020645A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011063127A1 (en) | 2009-11-18 | 2011-05-26 | University Of Medicine And Dentistry Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| US20120294800A1 (en) * | 2009-01-07 | 2012-11-22 | University Of Medicine And Dentistry Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| US8420084B2 (en) * | 2009-03-05 | 2013-04-16 | Medarex, Inc. | Fully human antibodies specific to CADM1 |
| US9849192B2 (en) | 2009-11-18 | 2017-12-26 | Rutgers, The State University Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| CA2887037A1 (en) | 2012-10-02 | 2014-04-10 | Rutgers, The State University Of New Jersey | Specific delivery of toxins conjugated with antibodies to activated matriptase |
| EA201690806A1 (ru) * | 2013-11-25 | 2016-09-30 | Оксфорд Байотерапьютикс Лтд. | Антитела |
| KR102441107B1 (ko) * | 2014-11-07 | 2022-09-13 | 후지쿠라 가세이 가부시키가이샤 | 데옥시하이푸신·신타제 유전자를 지표로서 사용하는 동맥 경화 및 암의 검출 방법 |
| AU2017235571B2 (en) | 2016-03-18 | 2024-05-16 | Georgetown University | Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7022821B1 (en) * | 1998-02-20 | 2006-04-04 | O'brien Timothy J | Antibody kit for the detection of TADG-15 protein |
| US5972616A (en) | 1998-02-20 | 1999-10-26 | The Board Of Trustees Of The University Of Arkansas | TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas |
| JP4778617B2 (ja) | 1999-03-12 | 2011-09-21 | ジョージタウン ユニバーシティ | マトリプターゼ、セリンプロテアーゼおよびその応用 |
| US7030231B1 (en) | 1999-09-30 | 2006-04-18 | Catalyst Biosciences, Inc. | Membrane type serine protease 1 (MT-SP1) and uses thereof |
| EP1226150A4 (en) * | 1999-10-20 | 2005-05-25 | Univ Arkansas | TADG-15: EXTRACELLULAR SERINE PROTEASE EXPRESSED IN CARCINOMA |
| US6447978B1 (en) | 1999-12-03 | 2002-09-10 | Kodak Polychrome Graphics Llc | Imaging member containing heat switchable polymer and method of use |
| JP2003521920A (ja) | 2000-02-03 | 2003-07-22 | コルバス・インターナショナル・インコーポレイテッド | 膜貫通セリンプロテアーゼをコードしている核酸分子、コードされたタンパク質、およびそれらに基づく方法 |
| US6903201B2 (en) | 2001-01-05 | 2005-06-07 | Curagen Corporation | Proteins and nucleic acids encoding same |
| AU2002305052A1 (en) | 2001-03-13 | 2002-09-24 | Corvas International, Inc. | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon |
| AU2002254357A1 (en) | 2001-03-22 | 2002-10-08 | Dendreon Corporation | Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon |
| US7105333B2 (en) | 2001-03-27 | 2006-09-12 | Deadreon Corporation | Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon |
| KR20040080940A (ko) | 2001-05-14 | 2004-09-20 | 덴드레온 코포레이션 | 트랜스막 세린 프로테아제 10을 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법 |
| US7019019B2 (en) | 2002-12-23 | 2006-03-28 | Dendreon Corporation | Matriptase inhibitors and methods of use |
| US8239547B2 (en) | 2004-07-09 | 2012-08-07 | Telefonaktiebolaget Lm Ericsson (Publ) | Method and arrangement for providing different services in a multimedia communication system |
| CA2592249C (en) | 2004-12-20 | 2014-07-29 | Amgen Fremont Inc. | Binding proteins specific for human matriptase |
| WO2006090389A2 (en) | 2005-02-24 | 2006-08-31 | Compugen Ltd. | Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof |
| WO2007047796A2 (en) * | 2005-10-17 | 2007-04-26 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
-
2008
- 2008-08-07 ES ES08795130.7T patent/ES2550754T3/es active Active
- 2008-08-07 JP JP2010519988A patent/JP5864856B2/ja not_active Expired - Fee Related
- 2008-08-07 AU AU2008284271A patent/AU2008284271B2/en not_active Ceased
- 2008-08-07 EP EP08795130.7A patent/EP2185933B1/en not_active Not-in-force
- 2008-08-07 DK DK08795130.7T patent/DK2185933T3/en active
- 2008-08-07 WO PCT/US2008/009512 patent/WO2009020645A2/en not_active Ceased
-
2010
- 2010-02-07 US US12/701,566 patent/US8420091B2/en not_active Expired - Fee Related
-
2014
- 2014-07-31 JP JP2014155821A patent/JP2014223083A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010535506A5 (enExample) | ||
| JP2009001563A5 (enExample) | ||
| JP2011509079A5 (enExample) | ||
| US9840551B2 (en) | Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof | |
| JP2008538289A5 (enExample) | ||
| Ayela et al. | Antibody–antigenic peptide interactions monitored by SPR and QCM-D: A model for SPR detection of IA-2 autoantibodies in human serum | |
| JP2015533788A5 (enExample) | ||
| JP2018042573A5 (enExample) | ||
| JP2013520174A5 (enExample) | ||
| JP2015172045A5 (enExample) | ||
| CA2633171A1 (en) | Antibodies against tumor-associated antigenic target (tat) polypeptides | |
| JP2012515226A5 (enExample) | ||
| JP2015523852A5 (enExample) | ||
| US8105598B2 (en) | Human monoclonal antibodies that specifically bind IGF-II | |
| JP2016536330A5 (enExample) | ||
| JP2010510809A5 (enExample) | ||
| RU2013113439A (ru) | Идентификация опухолеассоциированных антигенов для диагностики и терапии | |
| HRP20192347T1 (hr) | Antitijela prema klaudinu 18.2 koja su korisna u dijagnozi tumora | |
| KR20190003959A (ko) | Dpp3을 결정하는 방법 및 치료 방법 | |
| EP2257572A1 (en) | Human anti-mesothelin monoclonal antibodies | |
| JP2014223083A5 (enExample) | ||
| JP2014529297A (ja) | 新規な抗ｃｘｃｒ４抗体並びに癌の検出および診断のためのその使用 | |
| JP2014503180A5 (enExample) | ||
| JP2011501946A5 (enExample) | ||
| JP2013533732A5 (enExample) |